Atrish Bagchi

425 total citations
7 papers, 332 citations indexed

About

Atrish Bagchi is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Atrish Bagchi has authored 7 papers receiving a total of 332 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Atrish Bagchi's work include HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Atrish Bagchi is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Monoclonal and Polyclonal Antibodies Research (3 papers) and Lung Cancer Treatments and Mutations (3 papers). Atrish Bagchi collaborates with scholars based in United States, Netherlands and United Kingdom. Atrish Bagchi's co-authors include Kathryn M. Ferguson, Karl R. Schmitz, Paul M.P. van Bergen en Henegouwen, Rob C. Roovers, Mark A. Lemmon, Nicholas J. Bessman, Amélie Forest, Jason Walker, Jaafar N. Haidar and Ruslan D. Novosiadly and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Biophysical Journal and Cell Reports.

In The Last Decade

Atrish Bagchi

7 papers receiving 327 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Atrish Bagchi United States 5 220 190 126 54 54 7 332
Martine Darwish United States 9 232 1.1× 200 1.1× 173 1.4× 33 0.6× 98 1.8× 16 444
Michael M. Grandal Denmark 8 220 1.0× 136 0.7× 157 1.2× 48 0.9× 65 1.2× 11 375
Antonia Richter Germany 9 155 0.7× 202 1.1× 209 1.7× 45 0.8× 46 0.9× 15 443
Maureen Nerrie Australia 8 274 1.2× 205 1.1× 164 1.3× 36 0.7× 36 0.7× 11 407
Kathy Delaria United States 8 186 0.8× 276 1.5× 278 2.2× 27 0.5× 52 1.0× 8 417
Michael F. Giblin United States 10 136 0.6× 244 1.3× 129 1.0× 38 0.7× 21 0.4× 14 355
John J. Rhoden United States 6 142 0.6× 171 0.9× 106 0.8× 23 0.4× 47 0.9× 8 322
Martin Schwill Switzerland 7 242 1.1× 201 1.1× 146 1.2× 12 0.2× 37 0.7× 8 359
James Sanderson United States 10 167 0.8× 389 2.0× 136 1.1× 55 1.0× 35 0.6× 10 528
Jessica Bridoux Belgium 10 112 0.5× 265 1.4× 197 1.6× 32 0.6× 95 1.8× 17 374

Countries citing papers authored by Atrish Bagchi

Since Specialization
Citations

This map shows the geographic impact of Atrish Bagchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Atrish Bagchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Atrish Bagchi more than expected).

Fields of papers citing papers by Atrish Bagchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Atrish Bagchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Atrish Bagchi. The network helps show where Atrish Bagchi may publish in the future.

Co-authorship network of co-authors of Atrish Bagchi

This figure shows the co-authorship network connecting the top 25 collaborators of Atrish Bagchi. A scholar is included among the top collaborators of Atrish Bagchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Atrish Bagchi. Atrish Bagchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Bagchi, Atrish, Steven E. Stayrook, Katerina T. Xenaki, et al.. (2024). Structural insights into the role and targeting of EGFRvIII. Structure. 32(9). 1367–1380.e6. 3 indexed citations
2.
Nuñez-Cruz, Selene, et al.. (2023). F77 antigen is a promising target for adoptive T cell therapy of prostate cancer. Biochemical and Biophysical Research Communications. 680. 51–60. 6 indexed citations
3.
Bagchi, Atrish, Jaafar N. Haidar, Scott W. Eastman, et al.. (2017). Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance. Molecular Cancer Therapeutics. 17(2). 521–531. 46 indexed citations
4.
Ganetzky, Rebecca, Atrish Bagchi, Ornella Zollo, et al.. (2015). EGFR mutations cause a lethal syndrome of epithelial dysfunction with progeroid features. Molecular Genetics & Genomic Medicine. 3(5). 452–458. 11 indexed citations
5.
Bessman, Nicholas J., Atrish Bagchi, Kathryn M. Ferguson, & Mark A. Lemmon. (2014). Complex Relationship between Ligand Binding and Dimerization in the Epidermal Growth Factor Receptor. Cell Reports. 9(4). 1306–1317. 71 indexed citations
6.
Bagchi, Atrish, Nicholas J. Bessman, Neo Wu, et al.. (2014). Allosteric Regulation of the Epidermal Growth Factor Receptor. Biophysical Journal. 106(2). 105a–105a. 1 indexed citations
7.
Schmitz, Karl R., Atrish Bagchi, Rob C. Roovers, Paul M.P. van Bergen en Henegouwen, & Kathryn M. Ferguson. (2013). Structural Evaluation of EGFR Inhibition Mechanisms for Nanobodies/VHH Domains. Structure. 21(7). 1214–1224. 194 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026